Project Grant R01CA303246
Award Date 6/1/26
Completion Date 5/31/31
Dollars Obligated $502K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute awarded a $683,970 Project Grant to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Treatment Research program (CFDA 93.395) for the period April 1, 2026, through March 31, 2031. The award supports research into tumor-penetrating stromal modification of pancreatic ductal adenocarcinoma (PDAC) through investigation of the αvβ5 integrin pathway. The research focuses on...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $175,448 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, with completion targeted for July 31, 2027. This project grant supports research training and investigator development in cancer biology, specifically focused on characterizing cancer-associated fibroblasts (CAFs) and their role in pancreatic ductal adenocarcinoma (PDAC). The research aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a five-year Project Grant totaling $639,514 to The University of Texas Southwestern Medical Center (UT Southwestern) under the Cancer Biology Research program (CFDA 93.396), effective June 1, 2026, through May 31, 2031. The award supports fundamental cancer biology research focused on characterizing the catalytic mechanisms of NVL (a nucleolar AAA+ adenosine triphosphatase) inhibition by benzothiazepinone...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $402,011 Project Grant to The University of Texas Southwestern Medical Center (UT Southwestern) under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award funds fundamental research investigating the KEAP1-NRF2 redox sensing pathway's role in regulating CD8 T cell adaptation and stemness in the context of cancer and chronic infection. The research...
- The National Cancer Institute awarded a $357,370 Project Grant to The Leland Stanford Junior University on May 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC). The research focuses on understanding cancer-associated fibroblasts (CAFs), specifically a unique subpopulation of inflammatory CAFs implicated in PDAC's extensive fibrosis and...
- Federal Grant Award Summary The National Cancer Institute awarded The Wistar Institute of Anatomy and Biology a $780,764 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 15, 2026, with completion targeted for March 31, 2031. This research initiative investigates the role of branched-chain amino acid (BCAA) oxidation and signaling pathways in tumor-associated macrophages (TAMs) to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC). The...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $166,000 project grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective May 1, 2026 through April 30, 2028. This award supports research investigating novel therapeutic strategies to prevent resistance to KRAS inhibitors in pancreatic ductal adenocarcinoma (PDAC). The project focuses on combining pan-KRAS inhibitors with two innovative TRAIL...
- Federal Project Grant Award Summary The National Cancer Institute awarded The University of Texas Southwestern Medical Center a Cancer Treatment Research grant (CFDA 93.395) in the amount of $426,828 on May 4, 2026, with a project completion date of April 30, 2028. This project grant funds research to validate and translate discoveries regarding JUMONJI KDM5 histone demethylase enzymes as therapeutic targets for estrogen receptor-positive breast cancers that have developed resistance to CDK4/6...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a Project Grant of $408,829 under the Cancer Treatment Research program (CFDA 93.395) on May 25, 2026, with a completion date of April 30, 2028. This award funds investigative research into lipogenesis-mediated resistance to cytotoxic therapy in pancreatic ductal adenocarcinoma (PDAC). The research deliverables include characterization of de novo tumor lipid production following chemotherapy...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded Cold Spring Harbor Laboratory a $778,873 Project Grant on June 23, 2025, with a completion date of May 31, 2030. This award funds research to identify and validate SOAT1 (Sterol-O-Acyl Transferase 1) as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models and inducible degron systems...